EuroBiotech: More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> Shares in one of Neil Woodford’s funds fell 10% after Prothena reported the failure of a phase 2b trial. Woodford bet big on Prothena but, as with some of his previous investments including Circassia, has been stung. A statement by Woodford about the Prothena data was flooded with comments from investors questioning his approach. Statement

> Sofinnova Partners led a €26.5 million ($32.3 million) investment in EryDel. The Italian biotech will use the money to fund a phase 3 trial of its red-blood-cell-based drug delivery system. Release 

> Redx Pharma named Lisa Anson as its CEO. Anson, the former president of AstraZeneca in the U.K., arrives at Redx as it seeks to bounce back from financial troubles. Statement

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Autolus licensed a clinical-stage CD19 CAR-T therapy. The candidate is designed to improve on first-generation CD19 CAR-Ts by reducing side effects related to cytokine release syndrome. Release

> Boehringer Ingelheim entered into an antigen-specific tolerance induction collaboration with Topas Therapeutics. The agreement gives Boehringer an option to license preclinical candidates discovered in the collaboration. Statement 

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.